Interleukin 12 (IL-121, a multifunctional cytokine produced by macrophages and B-cell lines, induces interferon-y (IFN-y
I dimer composed of two subunits with molecular masses of 35 kD and 40 kD, is a multifunctional cytokine produced by macrophages, B-cell lines, and other cells.'-6 L-12 was
shown to stimulate the proliferation of activated T and natural killer (NK) ~ells,'*~*~.' to enhance specific and nonspecific cytolytic lymphocyte to induce interferon-y (IFN-y) production by NK and T and to promote the development of Thl-type helper T cell responses."- '3 In murine models, IL-12 demonstrates antitumor activity to- 
MATERIALS AND METHODS
Four-to six-week-old female BALBk nu/nu mice (National Cancer Institute, National Institutes of Health [NIH], Frederick, MD or Taconic, G e m t o w n , NY) maintained in pathogen-limited conditions were used throughout. Matrigel was prepared by H.K. Kleinman from the EnglebrethHolm-Swarm tumor as previously described." Recombinant human IF'-10 (0.06 endotoxin U/mg; Pepro Tech, Inc, Rocky Hill, NJ) was either purchased or provided by the National Cancer Institute. Recombinant murine IL-12 was a kind gift of Genetics Institute, Inc This assay was performed as described." Briefly, Matrigel (liquid at 4°C) was mixed with 150 ng/mL bFGF alone or in combination with either IP-10 or IL-12 at a final concentration of 400 ng/mL and 100 ng/mL, respectively. Matrigel alone, with bFGF, or with bFGF plus the test cytokine (total volume 0.5 mL), was injected subcutaneously into the midabdominal region of BALBk nude mice. After injection, the Matrigel polymerized to form a plug. After 6 days, the animals were killed, and the Matrigel plugs were removed together with the abstract epidermis and dermis, fixed in 10% neutral buffered formalin solution (Sigma Chemical In vivo matrigel assay. Neutralization experiments. In vivo neutralization experiments were performed by coinjection of a neutralizing or control antibody together with the Matrigel plus bFGF plus IL-12 injection mixture, followed by treatment of the mice with intraperitoneal (i.p.) injections of the same neutralizing or control antibody on days 1, 3, and 5 after subcutaneous Matrigel injection. The neutralizing murine IgG MoAb to murine I F N -Y~~ and the control murine IgG MoAb (Cappel) were added individually to the Matrigel injection mixture (0.5 mL Matrigel plus 150 ng/mL bFGF plus 100 ng/mL murine IL-12) at a final concentration of 1 mglmL; they were also injected individually i.p. at a dose of 1 mg/mouse in 0.3 mL of a formulation buffer (saline solution containing 50 mg/mL human serum albumin and 5 mg/mL mannitol; a gift of Dr J. Henkin, Abbott Laboratories, Abbott Park, IL). The neutralizing rabbit antiserum to murine IP-104' and the control rabbit antiserum (antihuman IL-6 peptide) were added individually to the Matrigel injection mixture at a dilution of 1 : 10; they were also injected individually ip (0.3 Wmouse) on days 1, 3, and 5 after subcutaneous Matrigel injection.
Isolation of RNA and reverse transcriptase-mediated polymerase chain reaction (RT-PCR). Total cellular RNA was isolated from either murine splenocytes or HUVEC by the guanidine thiocyanate/ CsCl centrifugation method, as described.43 Levels of cytokine mRNA were assessed by a semiquantitative RT-PCR as described.43 Briefly, RNA (4 pg) was reverse transcribed, using an Rnase Hreverse transcriptase (Superscript; Life Technologies, Inc, Gaithersburg, MD) according to the manufacturer's conditions. The resultant cDNA was immediately diluted with HzO to a final volume of 200 pL, without heating or Rnase H treatment. PCR was performed in thin-wall reaction tubes (Perkin Elmer Cetus, Norwalk, CT) in a reaction mixture (50 pL) containing cDNA, 200 pmol/L each dNTP, 1 pCi a-[32P]dCTP (3,000 CUmmol; Dupont-NEN, Boston, MA), 1 pmol/L each primer, 5% dimethyl sulfoxide (DMSO; Sigma Chemical Co), 1.5 mmoVL MgC12, and 2.5 U AmpliTaq DNA polymerase (Perkin Elmer Cetus) in reaction buffer supplied by the manufacturer. Primers are listed in Table 1 . The number of amplification cycles chosen empirically for each primer pair was such that the maximum signal intensity for a set of samples was within the linear portion of a product versus template amplification c~r v e . 4~ Amplifications were performed in a thermocycler (Gene Amp PCR System 9,600; Perkin Elmer Cetus) as follows: 94"C, 45 seconds; primer annealing temperature as specified in Table 1 ,45 seconds; 72°C 45 seconds); and maintenance at 4°C until analysis. Aliquots (50 pL) of each amplification reaction were analyzed by electrophoresis on 7% acrylamide (Long Ranger; AT Biochem, Malvem, PA) Trisborate EDTA gels, followed by autora&ography and quantitation by Phosphorimage analysis (Molecular Dynamics, Sunnyvale, CA). DNA sizes were determined using mobility standards derived by T4 DNA polymerase end-labeling of Gel Marker DNA (Research Genetics, Huntsville, AL).
Arithmetic means, standard deviations, and Student's t-test were calculated by conventional formulas using Systat for the Machintosh (Systat Inc, Evanston, IL).
Statistical analysis.

RESULTS
In initial experiments, we tested the effects of IL-12 on neovascularization using a mouse model in which subcutaneous injection of basement membrane (Matrigel) impregnated with bFGF induces new vessel formation. Athymic mice, selected to exclude potential contributions by immune T cells, were injected subcutaneously with Matrigel alone, Matrigel plus bFGF (150 ng/mL), Matrigel plus bFGF (150 ng/ mL) plus human IP-10 (400 ng/mL), or Matrigel plus bFGF (150 ng/mL) plus murine IL-12 (100 ng/mL), all in a final volume of 0.5 mL. Matrigel plugs, removed from the mice 6 days after injection and processed for histology, were analyzed for cell invasion. Previous studies have established that the cells invading bFGF-impregnated Matrigel plugs are mostly endothelial cells." In a representative experiment (Fig l) , plugs of Matrigel alone contained few infiltrating cells, accounting for a mean surface area of 104 pm2/field (4 X lo4 pm'). Matrigel plugs impregnated with bFGF contained 12.4-fold more infiltrating cells compared with plugs of Matrigel alone (mean surface area 1,290 pm'/field), indicative of bFGF-induced neovascularization. Matrigel plugs with IL-12 added together with bFGF contained significantly fewer cells compared with Matrigel plus bFGF plugs (mean surface area 269 pm'held, P < .001). These results are indicative of IL-12-induced inhibition of neovascularization. As reported previously, IP-10 suppressed bFGF-induced neovascularization of Matrigel plugs (mean surface area 412 pm2/field). These experiments confirm, in another model system, that IL-12 can act as a potent inhibitor of neovascularization in vivo. Because these studies used athymic mice, the results further indicate that the antiangiogenic effect of IL-12 is not dependent on the participation of immune T cells.
To assess whether the antiangiogenic activity of IL-12 could be caused by IP-10 induction, we first looked for IFN- y and IP-IO gene expression in athymic mouse splenocyte cultures induced with murine IL-12. To this end, splenocytes (3 X IOh cells/mL) from two 6-week-old BALB/c nuhu mice were incubated for 5 to 30 hours in either medium alone, LPS (100 ng/mL), or IL-12 ( I O ng/mL). At the end of culture, the presence of IFN-y and IP-IO mRNAs was assessed through reverse transcription and PCR amplification using specific primers followed by gel electrophoresis of the PCR products. The results show that murine IL-12 induces both murine IFN-y and murine IP-IO gene expression in splenocytes after 5 , 24, and 30 hours of exposure (Fig 2A) . Because both IFN-y and IP-IO mRNAs were detectable at the earliest time point (5 hours) tested after IL-12 stimulation, a temporal relationship between IFN-y and IP-IO induction by IL-12 could not be established. However, primary cultures of human umbilical cord endothelial cells (HUVEC) were incubated in medium alone, or in medium supplemented with either human IL-12 ( I O ng/mL) or human IFN-y (I00 ng/mL) to assess whether IFN-y is required for IP-IO gene expression. Cultures were obtained after a 6-or 24-hours incubation. RNA was extracted, and expression of human IP-IO was examined after reverse transcription and PCR amplification using specific primers. IFN-y induced IP-IO expression in HUVEC at both time points whereas IL-12 did not (Fig 2B) . Consistent 
DISCUSSION
The present experiments show that IP-IO is the downstream molecule primarily responsible for inhibition of angiogenesis by IL-12. In addition, these experiments confirm that inhibition of angiogenesis by IL-12 is mediated by IFN-Y ,~' an inducer of IP-IO.Js.J" In these experiments. the antibody to murine IFN-y completely neutralized the effects of IL-12, whereas the antiserum to murine IP-I O substantially reduced. but not completely removed. IL-I2 inhibition. Also. IL-I2 inhibited angiogenesis to a somewhat greater extent than IP-IO. One interpretation of these experiments is that IL-12 is a more potent inhibitor of angiogenesis than IP-IO. or indirectly by IL-12, contribute to inhibition of angiogenesis by IL-12. An alternative possibility is that the IP-IO used here may not express its full biologic potential, andor that the antiserum to murine IP-IO may not display optimal neu- BALB/c nu/nu female mice (3 mice per condition) were injected subcutaneously with either Matrigel alone, Matrigel plus bFGF (150 ng/mL), Matrigel plus bFGF (150 ng/mL) and murine IL-12 (100 nglml) alone or together with control or neutralizing antibodies to either IFNy or IP-10. or Matrigel plus bFGF (150 ng/mL) and human IP-10 (400 ng/mL). The mice injected subcutaneously with Matrigel plus IL-12 plus antibodies were also injected intraperitoneally with the appropriate antibodies on day 1 and again 3 and 5 days later. The Matrigel plugs were removed 6 days after inoculation and processed for histology. The results reflect the mean (+SD) surface area (pm2) occupied by cells/field (4 x 10' pm2) for each group of mice.
tralizing capacity for murine IP-IO. at least in comparison to the anti IFN-7 antibody used in parallel.
Only recently has inhibition of angiogenesis been identified as a biologic property of IP-10:~"~"' In two distinct in vivo models, the rat corneal micropocket and the mouse Although further studies will be needed to characterize the mechanisms underlying the antitumor effects of IL-12, the present studies establish the important role played by IP-IO as a downstream mediator of the antiangiogenic effects of IL-12. A more complete understanding of cytokine networks will lead to more rational approaches to therapy.
